FUGAZZOLA, LAURA
FUGAZZOLA, LAURA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer
2025 V. Cirello, C. Colombo, D. Tosi, A. Manzo, M.O. Borghi, U. Gianelli, G. Gazzano, S. Ferrero, G. Dionigi, L. Persani, L. Fugazzola
Impatto della dose iniziale sul trattamento con lenvatinib nel carcinoma tiroideo differenziato avanzato
2025 C. Moneta, M. Trevisan, C. Colombo, M. Succi, M. Lugaresi, D. Ceruti, S. De Leo, L. Fugazzola
La lobectomia come trattamento iniziale del carcinoma midollare tiroideo sporadico: uno studio prospettico
2025 M. Lugaresi, A. De Luca, G. Saruggia, G. Dionigi, G. Gazzano, M. Muzza, L. Persani, C. Colombo, L. Fugazzola
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors
2025 M. Muzza, C. Colombo, G. Pogliaghi, E. Carbone, L. Ermellino, M. Succi, C. Moneta, G. Dionigi, D. Gentilini, G. Vannucchi, G. Gazzano, L. Persani, L. Fugazzola
Utility of ultra-portable ultrasound devices for the risk-stratification of thyroid dysfunctions in an emergency setting
2025 I. Campi, L. Fugazzola
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations
2025 C. Colombo, S. De Leo, I. Campisi, E. Palesandro, F. Turco, C. Buttigliero, L. Fugazzola, M. Tucci
Beyond Malignancy Risk Stratification: FNAC Report Anticipates Thyroid Cancer Staging. Insights From Recent Studies
2025 M. Rotondi, M. Endo, M. Teliti, A. Crescenzi, I. Azaryan, L. Croce, R. Elisei, L. Fugazzola, E.S. Cibas, P. Trimboli, J.A. Sipos
Changing the paradigm: lobectomy for sporadic medullary thyroid cancer
2025 M. Lugaresi, C. Moneta, G. Saruggia, G. Dionigi, G. Gazzano, L. Fugazzola
Will the autofluorescence take over inadvertent parathyroidectomy?Results from a multicentre cohort study
2025 D. Barbieri, P. Indelicato, S. DE LEO, C. Moneta, S. Coccia, G. Gazzano, L. Giordano, F. LIRA LUCE, D. Canta, L. Fugazzola, M. Bussi, G. Dionigi, M. Trevisan
Thyroid cancer and endocrine disruptive chemicals: a case–control study on per-fluoroalkyl substances and other persistent organic pollutants
2024 V. Cirello, M. Lugaresi, C. Moneta, P. Dufour, A. Manzo, E. Carbone, C. Colombo, L. Fugazzola, C. Charlier, C. Pirard
Mitochondrial DNA and Ischemia Reperfusion Injury: Development of an Experimental Extra Corporeal Lung Perfusion (EVLP) Rat Model
2024 L. Rosso, I. Righi, C. Lonati, M. Battistin, M. Pinti, M. Cattaneo, V. Selleri, I. Campi, L. Fugazzola, M. Nosotti
Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
2024 C. Colombo, D. Ceruti, M. Succi, S. De Leo, M. Trevisan, C. Moneta, L. Fugazzola
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update
2024 L.A. Bischoff, I. Ganly, L. Fugazzola, E. Buczek, W.C. Faquin, B.R. Haugen, B. Mciver, C.P. Mcmullen, K. Newbold, D.J. Rocke, M.D. Russell, M. Ryder, P.M. Sadow, E. Sherman, M. Shindo, D.C. Shonka, M.C. Singer, B.C. Stack, L.J. Wirth, R.J. Wong, G.W. Randolph
Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe
2024 C. de la Fouchardière, L. Fugazzola, L.D. Locati, C.V. Alvarez, R.P. Peeters, P. Camacho, I.M. Simon, B. Jarząb, R. Netea-Maier
Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations
2024 L. Fugazzola, M. Deandrea, S. Borgato, M. Dell'Acqua, F. Retta, A. Mormile, C. Carzaniga, G. Gazzano, G. Pogliaghi, M. Muzza, L. Persani
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
2024 J.S. Rodrigues, M. Chenlo, S.B. Bravo, S. Perez-Romero, M. Suarez-Fariña, T. Sobrino, R. Sanz-Pamplona, R. González-Prieto, M.N. Blanco Freire, R. Nogueiras, M. López, L. Fugazzola, J.M. Cameselle-Teijeiro, C.V. Alvarez
Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model
2024 V. Ghiandai, E.S. Grassi, G. Gazzano, L. Fugazzola, L. Persani
Extra-nuclear TERT counteracts oxidative stress and promotes progression in papillary thyroid carcinoma
2024 M. Muzza, G. Pogliaghi, C. Colombo, E.S. Grassi, E. Carbone, S. Palazzo, F. Frattini, G. Gazzano, L. Persani, L. Fugazzola
A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study
2023 G. Grani, M. Gentili, F. Siciliano, D. Albano, V. Zilioli, S. Morelli, E. Puxeddu, M.C. Zatelli, I. Gagliardi, A. Piovesan, A. Nervo, U. Crocetti, M. Massa, M.T. Samà, C. Mele, M. Deandrea, L. Fugazzola, B. Puligheddu, A. Antonelli, R. Rossetto, A. D'Amore, G. Ceresini, R. Castello, E. Solaroli, M. Centanni, S. Monti, F. Magri, R. Bruno, C. Sparano, L. Pezzullo, A. Crescenzi, C. Mian, D. Tumino, A. Repaci, M.G. Castagna, V. Triggiani, T. Porcelli, D. Meringolo, L. Locati, G. Spiazzi, G. Di Dalmazi, A. Anagnostopoulos, S. Leonardi, S. Filetti, C. Durante
Targeting the DNA damage response kinase Chk1 in TP53-mutated aggressive thyroid cancers: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani